Efficacy of First-Line Letrozole Versus Tamoxifen as a Function of Age in Postmenopausal Women with Advanced Breast Cancer

Autor: H. Mouridsen, H. A. Chaudri-Ross
Rok vydání: 2004
Předmět:
Zdroj: The Oncologist. 9:497-506
ISSN: 1549-490X
1083-7159
Popis: Learning Objectives After completing this course, the reader will be able to: Identify those patients in both age groups who responded most favorably to first-line therapy with letrozole. Describe the advantages of first-line treatment with letrozole in older patients with advanced breast cancer. Discuss the role of first-line therapy with letrozole in the management of advanced breast cancer. Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com Purpose. To compare the efficacy, in regard to time to progression (TTP) and objective response rate (ORR), of letrozole (Femara®; Novartis Pharma AG; Basel Switzerland), an oral aromatase inhibitor, with that of tamoxifen (Tamofen®; Leiras OY; Turku, Finland) as first-line therapy in younger ( Materials and Methods. Nine hundred seven patients with advanced breast cancer were randomly assigned to receive 2.5 mg letrozole (n = 453) or 20 mg tamoxifen (n = 454) once daily in a double-blind, multicenter, international trial. Among the prospectively planned analyses were analyses of TTP and ORR by age ( Results. Letrozole was as effective in older postmenopausal women (≥70 years of age) as it was in younger postmenopausal women ( Conclusion. The data show that letrozole, 2.5 mg once daily, is as effective in older, postmenopausal women as it is in younger postmenopausal women with advanced breast cancer. In addition, letrozole was more effective than tamoxifen in both younger and older patients.
Databáze: OpenAIRE
Externí odkaz: